
Fluidigm Corporation Balance Sheet 2011-2026 | FLDM
Annual Balance Sheet Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.38 M | 69.1 M | 76.7 M | 142 M | 184 M | 232 M | 243 M | -35.3 M | -58.6 M | -3.42 M |
Long Term Debt |
54.2 M | 53.8 M | 172 M | 195 M | 195 M | 196 M | 195 M | - | - | 1.22 M |
Total Non Current Liabilities |
131 M | 78.4 M | 194 M | 223 M | 224 M | 226 M | 228 M | 2.55 M | 1.48 M | 2.26 M |
Total Current Liabilities |
54.2 M | 32.8 M | 37.6 M | 33.5 M | 29.5 M | 30.1 M | 29.4 M | 18 M | 11.6 M | 20.2 M |
Total Liabilities |
186 M | 111 M | 232 M | 256 M | 253 M | 256 M | 257 M | 20.5 M | 13.1 M | 22.4 M |
Deferred Revenue |
13.5 M | 11.8 M | 11.5 M | 10.2 M | 9.16 M | 9.42 M | 6.93 M | 2.72 M | 1.89 M | 2.01 M |
Retained Earnings |
- | -624 M | -559 M | -500 M | -439 M | -363 M | -310 M | -257 M | -241 M | -222 M |
Total Assets |
325 M | 265 M | 304 M | 287 M | 306 M | 371 M | 408 M | 117 M | 114 M | 79.3 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Fluidigm Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Bioventus
BVS
|
$ 9.19 | 2.06 % | $ 612 M | ||
|
Biodesix
BDSX
|
$ 15.31 | 4.22 % | $ 1.99 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Lantheus Holdings
LNTH
|
$ 74.11 | -2.15 % | $ 5 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Medpace Holdings
MEDP
|
$ 463.46 | 1.43 % | $ 13.4 B | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
$ 159.84 | 1.16 % | $ 7.92 B | ||
|
IQVIA Holdings
IQV
|
$ 165.65 | -0.81 % | $ 28.5 B | ||
|
Myriad Genetics
MYGN
|
$ 4.67 | 0.11 % | $ 432 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
National Research Corporation
NRC
|
$ 17.26 | -1.46 % | $ 386 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
$ 1.22 | -16.44 % | $ 6.64 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 261.71 | 1.72 % | $ 26 B | ||
|
Interpace Biosciences
IDXG
|
$ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
$ 125.17 | 1.11 % | $ 19.9 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.38 | -1.08 % | $ 414 M | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Precipio
PRPO
|
$ 27.01 | 0.3 % | $ 35.1 M | ||
|
Celcuity
CELC
|
$ 101.12 | -5.27 % | $ 3.99 B | ||
|
Personalis
PSNL
|
$ 7.67 | 0.72 % | $ 454 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 266.56 | 0.81 % | $ 22.2 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
RadNet
RDNT
|
$ 59.22 | -4.09 % | $ 4.45 B | ||
|
ENDRA Life Sciences
NDRA
|
$ 3.49 | 0.29 % | $ 1.87 M | ||
|
NeoGenomics
NEO
|
$ 7.87 | -2.82 % | $ 1.01 B | ||
|
Natera
NTRA
|
$ 193.75 | -3.17 % | $ 19.1 B | ||
|
Senseonics Holdings
SENS
|
$ 6.63 | 0.08 % | $ 277 M | ||
|
Sotera Health Company
SHC
|
$ 13.82 | -0.43 % | $ 3.92 B | ||
|
CareDx, Inc
CDNA
|
$ 17.65 | 0.51 % | $ 941 M | ||
|
Soleno Therapeutics
SLNO
|
$ 30.84 | -2.77 % | $ 1.57 B | ||
|
OPKO Health
OPK
|
$ 1.14 | -1.3 % | $ 791 M | ||
|
Castle Biosciences
CSTL
|
$ 25.23 | -2.02 % | $ 701 M | ||
|
DarioHealth Corp.
DRIO
|
$ 8.05 | 7.27 % | $ 32.1 M | ||
|
DexCom
DXCM
|
$ 66.28 | 0.51 % | $ 25.9 B | ||
|
Neuronetics
STIM
|
$ 1.47 | -8.12 % | $ 96.9 M | ||
|
Exact Sciences Corporation
EXAS
|
$ 104.91 | - | $ 19.8 B |